Summary:
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Crossover, Multicenter Clinical Study to Assess the Efficacy and Safety of Once Daily Administration of Lupin Tiotropium Bromide Inhalation Powder Compared to SPIRIVA HANDIHALER and Placebo in Patients with COPD including a 12-week Open-Label Extension to Assess Inhaler Robustness.
Qualified Participants Must:
Be Male or Female patients 40 years of age and older, inclusive as of the screening visit (visit 1)
Have a diagnosis of COPD
Be a current smoker or non-smoker with a minimum 10 pack-years of historical use, the equivalent of one pack per day for 10 years
If female of childbearing potential and committed to consistent and correct use of an acceptable method of birth control
Qualified Participants May Receive:
Can get compensated up to $1,150, free treatment and doctor consultations with 24hr emergency phone line.